Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Eve vs Trimrose

Eve
Graded #210

Higher grade

vs+10.799999999999997
Trimrose
Graded #446

Lower grade

The verdict

Eve takes it — 66/100 to 55.2/100.

Eve grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Eve is a women's-health-focused GLP-1 telehealth platform — distinctive positioning in a largely gender-neutral market — offering both compounded semaglutide and tirzepatide (including an oral sublingual…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEve +15
54
39
Dose & formulationEve +24
88
64
Clinical oversightEve +11
79
68
Labs & monitoringEven
52
52
FulfillmentEve +10
67
57
Contract termsTrimrose +14
41
55
Eve · left barTrimrose · right bar

The numbers

MetricEveTrimrose
WeighScore66/10055.2/100
GradeCC
Scorecard rank#210#446
Semaglutide$195/mo (compounded)Not disclosed
Tirzepatide$195/mo (compounded)Not disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
Eve

Graded #210 · C

Strengths

  • Genuinely women's-health-focused — fills a real gap among gender-neutral GLP-1 competitors
  • Both compounded and brand-name FDA-approved options (Wegovy/Ozempic/Mounjaro) on one platform — rare
  • LegitScript Certified with a verifiable ID
  • Publishes the FDA compounded-medication disclaimer
  • Oral sublingual semaglutide offered alongside injectable

Where it loses points

  • Full states-served list not disclosed publicly
  • 503A pharmacy partner not named, and 503A vs 503B status not specified
  • Named medical director / clinical leadership not disclosed
  • Corporate legal entity not disclosed
  • Governing law / arbitration venue not stated
Trimrose

Graded #446 · C

Strengths

  • Free, no-cost, no-obligation online eligibility quiz before any commitment
  • Offers a choice of a weekly compounded GLP-1 injection or a daily oral option
  • Fully online — assessment, provider review, and home delivery with ongoing support

Where it loses points

  • Runs on the CareValidate white-label platform and isn't the medical provider itself — a support@carevalidate.com address is exposed on the site
  • Pricing isn't shown publicly; the cost and the specific compounded molecule appear only after you complete the eligibility quiz
  • The states served, pharmacy partner and any LegitScript/503A certification aren't disclosed on the public site
  • Markets 'up to 22.5% of body weight' — a trial figure for branded tirzepatide, not a guaranteed or compounded-specific outcome
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard